Literature DB >> 11389500

Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis.

K Gupta1, D F Sahm, D Mayfield, W E Stamm.   

Abstract

Current recommendations for empirical therapy for community-acquired urinary tract infection (UTI) in women hinge on knowledge of antimicrobial susceptibility patterns in the geographic region of the practitioner. We conducted a survey of antimicrobial susceptibilities of 103,223 isolates recovered from urine samples that were obtained in 1998 from female outpatients nationally and within 9 geographic regions in the United States. Resistance of Escherichia coli isolates to trimethoprim-sulfamethoxazole varied significantly according to geographic region, ranging from a high of 22% in the western United States to a low of 10% in the Northeast (P<.001). There were no clinically significant age-related differences in the susceptibility of E. coli to any of the study drugs, but the susceptibility to fluoroquinolones of non-E. coli isolates that were recovered from women who were aged >50 years was significantly lower than that of isolates recovered from younger women (P<.001). The in vitro susceptibility of uropathogens in female outpatients varies according to age and geographic region.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389500     DOI: 10.1086/320880

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  67 in total

1.  Empirical treatment of uncomplicated cystitis.

Authors:  A Baerheim
Journal:  BMJ       Date:  2001-11-24

2.  Management of uncomplicated urinary tract infections.

Authors:  Timothy Jancel; Vicky Dudas
Journal:  West J Med       Date:  2002-01

3.  Vaccine Development for the Prevention of Urinary Tract Infections.

Authors:  Walter J. Hopkins; David T. Uehling
Journal:  Curr Infect Dis Rep       Date:  2002-12       Impact factor: 3.725

4.  In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.

Authors:  Laurel S Almer; Jennifer B Hoffrage; Erika L Keller; Robert K Flamm; Virginia D Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

Review 5.  Probiotics. Some evidence of their effectiveness.

Authors:  Gregor Reid; Jo-Anne Hammond
Journal:  Can Fam Physician       Date:  2005-11       Impact factor: 3.275

6.  Virulence genotype and phylogenetic origin in relation to antibiotic resistance profile among Escherichia coli urine sample isolates from Israeli women with acute uncomplicated cystitis.

Authors:  James R Johnson; Michael A Kuskowski; Timothy T O'bryan; Raul Colodner; Raul Raz
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

7.  Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection.

Authors:  Ann E Stapleton; Melissa Au-Yeung; Thomas M Hooton; David N Fredricks; Pacita L Roberts; Christopher A Czaja; Yuliya Yarova-Yarovaya; Tina Fiedler; Marsha Cox; Walter E Stamm
Journal:  Clin Infect Dis       Date:  2011-04-14       Impact factor: 9.079

8.  Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States.

Authors:  James A Karlowsky; Laurie J Kelly; Clyde Thornsberry; Mark E Jones; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Community-acquired antibiotic resistance in urinary isolates from adult women in Canada.

Authors:  Warren J McIsaac; Tony Mazzulli; Joanne Permaul; Rahim Moineddin; Donald E Low
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-11       Impact factor: 2.471

10.  Uropathogen antibiotic resistance in adult women presenting to family physicians with acute uncomplicated cystitis.

Authors:  Warren J McIsaac; Tony Mazzulli; Rahim Moineddin; Janet Raboud; Susan Ross
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-09       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.